AGENDA 

 

Pre-Conference Workshop Day - Monday 30th March 2020

PRE-CONFERENCE WORKSHOP DAY - Monday 30th March 2019

12:00

Networking Lunch

LOGISTICS/DELIVERY TO PATIENT
13:00

Tech transfer forum: tools, tactics, strategies and approaches

PRICING & MARKET ACCESS
13:00

Title TBC (Pricing and Market Access)

BIOPROCESS
13:20

Title TBC (BIOPROCESS)

PRICING & MARKET ACCESS
13:20

Title TBC (Pricing and Market Access)

BIOPROCESS
13:40

Title TBC (BIOPROCESS)

CORD BLOOD
14:00

CB Expansion breakthrough

BIOPROCESS
14:20

Title TBC (BIOPROCESS)

CORD BLOOD
14:20

TBC Driving public banked cord blood inventory utilization through research and development

BIOPROCESS
14:40

Title TBC (BIOPROCESS)

RARE DISEASE
14:40

Title TBC (RARE DISEASE)

CORD BLOOD
14:40

Title TBC (CORD BLOOD)

15:00

Afternoon Networking Break

17:30

Close of Conference for the day - Opening Networking drinks reception at the Business Design Center

last published: 06/Dec/19 09:35 GMT

Conference Day 1 - Tuesday 31st March 2020

CONFERENCE DAY 1 - TUESDAY 31st March 2020

Opening Keynotes Day 1 – CAR-T & Immunotherapy focus

Prasad Adusumilli
09:00

Keynote presentaton: Autologous Mesothelin-targeting CAR-T to tackle solid tumours in the clinic

  • The presentation will highlight results to date of mesothelin-targeted CAR T-cell clinical trial results
  • Advances in preclinical research of CAR T-cell therapy for solid tumors will be presented
  • Novel strategies for overcoming hurdles to solid tumor CAR T-cell therapy will be discussed
Panel discussion
09:20

Realizing the promise of ATMPs for patients around the world

  • Working with regulators to navigate scale up challenges in manufacturing
  • Strategies in supply chain and patient delivery
  • Tackling post manufacturing commercialization challenges such as pricing and finding highly skilled experts
  • Durability
10:20

Morning Coffee Break

Mark Sawicki
11:40

Effective Integration Strategies Through a Compliance Unified Ecosystem (CUE)

  • Systems Integration continues to be a major issue in the production and distribution of Advanced Therapies
  • Well-defined strategies for the integration of independent informatics platforms will be critical for future standardization and workflow optimization
  • Cryoport’s Compliance Unified Ecosystem (CUE) is driving standard practices for systems integration in the industry
round tables
12:00

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for you

Technology and Strategy Roundtables will run from 12:00-12:45 with 15 minutes for a quick summary from each table at the front of the room. These will take place in the conference rooms: look for your table number to participate.
1. Raw material supply for the commercial manufacturing of cell and gene therapies
Frank Hecht

Frank Hecht, Vice President Marketing And Sales, CellGenix GmbH

11. Cord blood as a source of new cells
12. Tissue engineering for organ regeneration
Vaidehi Joshi

Vaidehi Joshi, Scientist II, Therapeutics,, Organovo

13. TBC
14. Making allogeneic cell therapy a reality
Devyn Smith

Devyn Smith, Chief Operating Officer and Head Of Strategy, Sigilon

15. Industry-no profit alliances: how to optimize synergies
Elena Beltrami

Elena Beltrami, Business Development Manager, Fondazione Telethon

17. How companies can interact with the regulator and various pitfalls to be aware of
John Johnston

John Johnston, Clinical Assessor, Medicines & Healthcare Products Regulatory Agency

19. Roundtable available
2. Physiological conditions and analytical and monitoring tools for 3D cell cultivations
Cornelia Kasper

Cornelia Kasper, Professor, Biopharmaceutical Production And Technology, B.O.K.U.

21. Neurological applications for ATMPs
22. Development of regenerative medicines for cardiovascular indications
David Mazzo

David Mazzo, Chief Executive Officer, Caladrius Biosciences

23. Renal applications for ATMPs
24. Tackling diabetes with ATMPs
3. TBC (Reserved for Schott)
Sebastian Kress

Sebastian Kress, Post Doc, BOKU

5. Considerations for manufacture scale-up from academia to commercial manufacturing
Johannes Van Der Loo

Johannes Van Der Loo, Clinical Vector Core Director, The Children's Hospital of Philadelphia

9. Exploring the crossover between human and veterinary applications for stem cells
Joanna Miller

Joanna Miller, Chief Scientific Officer, Cell Therapy Sciences

13:00

Lunch

STEM CELLS & REGEN MED
14:40

Industrialized personalized regenerative medicine, promising but very challenging

PRICING & MARKET ACCESS
14:40

Improving market access for USA, UK and Europe

GENE MODIFIED CELL THERAPY
14:40

Macrophages to tackle solid tumors: innate and adaptive immunity

RESEARCH & DEVELOPMENT
15:00

TBC (RESEARCH & DEVELOPMENT)

GENE MODIFIED CELL THERAPY
15:20

TBC Trilogy cells: a new approach to tackling solid tumours

PITCH AND PARTNER
15:50

Regenerative medicine – a small molecule approach

GENE EDITING
16:00

Development of therapeutic genome editing strategies

Seokjoong Kim, Executive Director Of R&D And Strategic Alliances, ToolGen
GENE MODIFIED CELL THERAPY
16:00

TCR-Engineered T Cells for the Treatment of Solid Cancer: Maximising Scale and Benefit for NY-ESO TCR-T

Cedrik Britten, Head Of Cell Therapy, GSK
16:20

Afternoon Break

PATIENT DELIVERY
17:00

Traceability in the clinic: best practices, new opportunities

PITCH AND PARTNER
17:00

Why Specialised Logistics

Timothy Davies, Business Development Manager, A4P Bio
GENE MODIFIED CELL THERAPY
17:00

A new TCR approach to take solid tumours

Namir Hassan, Chief Scientific Officer, Zelluna Immunotherapy
GENE THERAPY
17:00

AAV gene therapy

RESEARCH & DEVELOPMENT
17:20

Gene Therapy for neurological disorders

Mimoun Azzouz, Neuroscience Professor, University of Sheffield
GENE THERAPY
17:20

Panel discussion: Immunogenicity for gene therapy

Key unresolved clinical issues in gene therapy: immunosuppression, re-dosing, and in-utero dosing
18:00

Close of Conference for the day - Please join us for an evening drinks reception at the iconic Emirates Stadium

last published: 06/Dec/19 09:35 GMT

Conference Day 2 - Wednesday 1st April 2020

08:55

Opening Remarks

Federico Mingozzi
09:00

Gene therapy 2.0: New clinical data, therapeutic applications and next generation technologies

  • Latest updates on LUXTURNA studies to treat blindness, haemophilia and rare disease
  • Tackling the challenges of viral gene therapies i.e. immunogenicity
  • Developing the next generation of gene therapies, what does the future hold?
Steve Kanner
09:20

Next-generation gene editing technology for allogeneic immune cell therapeutics

  • Next-generation CRISPR-Cas9 technology
  • Significantly enhanced editing specificity
  • Editing in immune cells for generation of functionally tuned therapeutics
Adrian Woolfson
09:40

Repairing the human genome with designed zinc finger editing reagents

  • Overview of Sangamo’s zinc finger protein gene editing technology, including new innovations that facilitate specificity, precision, and gene editing efficiency
  • Will address specific examples of defined therapeutic applications including the generation of reagents suitable for use in tauopathies, Huntington’s disease, and lysosomal storage diseases
Frederic Chereau
10:00

In vivo gene editing paediatric patients with rare diseases

10:20

Networking Refreshments

IMMUNOTHERAPY
11:20

Immuno-oncology for breast cancer

13:00

Neworking Lunch

IMMUNOTHERAPY
14:40

Gene modified Cell Therapy: Gene modified T-Cells for solid tumours

STEM CELLS & REGEN MED
15:00

Commercialising the first cell therapy in Europe, lessons learned

16:20

Networking refreshments

INNOVATION
17:00

Stem cells secretome and their efficiency in the treatment of soft tissue injury and skin rejuvenation

INNOVATION
17:20

Cell manufacturing for cell therapy and regenerative medicine and cell expansion for iPSCs

RESEARCH & DEVELOPMENT
17:40

Therapeutic potentials of activated islet progenitor cells for the treatment of diabetes

CELL THERAPY MANUFACTURE
17:40

Industrial automation of cell therapy manufacturing

GENE EDITING
17:40

mRNA characterization

RESEARCH & DEVELOPMENT
18:00

In vivo models, safety and preclinical development of engineered exosome therapeutics for NPC1 and Lysosomal Storage Disease

CELL THERAPY MANUFACTURE
18:00

Panel discussion: Building your own manufacturing facility Vs. outsourcing the process to partners

last published: 06/Dec/19 09:35 GMT